Picture a shopper on an insurance marketplace comparing two silver plans. One has a $4,500 deductible and 30% coinsurance. The other has a $3,000 deductible, but primary care visits count toward it, and drugs carry a separate deductible. Which plan will cost her less over a year? Most people cannot say with confidence, and research suggests many guess wrong.

Standard plan designs are a policy response to this problem. Regulators prescribe the cost-sharing structure: the deductible, the copays, and which services are covered before the deductible is met. Plans within a tier then differ mainly in premium, provider network, and insurer. Covered California, Massachusetts, New York, and several other states have used versions of this approach for years, and federal marketplace rules have moved back and forth on it across administrations.

The question is whether the trade works. Standardization promises clearer choices and sharper price competition. Critics warn that it limits innovation and pushes differentiation into less visible corners of the market. The evidence suggests both sides are partly right, and the specific design choices determine which effect dominates.

Standardization is not a single policy. It is a range of approaches. At the lightest end sit the Affordable Care Act's metal tiers. Each plan must hit an actuarial value target of roughly 60% for bronze, 70% for silver, 80% for gold, and 90% for platinum. Actuarial value is the share of expected medical costs a plan covers for a standard population. Within that target, insurers can arrange deductibles, copays, and coinsurance however they like.

That flexibility is substantial. Two silver plans with identical actuarial value can feel very different to use. One might pair a low deductible with high coinsurance. Another might carry a high deductible but cover generic drugs and office visits from the first dollar. Metal tiers standardize the average, not the experience. A person managing diabetes and a person who rarely sees a doctor can find the same 70% plan worth very different amounts.

The middle of the spectrum holds hybrid models. Insurers must offer at least one standardized plan per tier but may also sell their own designs, sometimes subject to caps on how many non-standard plans they can offer. At the far end are fully prescribed designs. Covered California specifies cost-sharing for essentially every plan on its exchange. Medigap is the oldest American example. Since the early 1990s, Medicare supplemental policies have been sold under lettered designs, so Plan G from one insurer covers the same benefits as Plan G from another.

Where a market lands depends on more than design philosophy. In John Kingdon's terms, policy options circulate for years until problems, politics, and proposals align. Full standardization took hold first in states with active-purchaser exchanges and a political consensus around consumer protection. Elsewhere, it advanced only as evidence of consumer confusion piled up and federal rulemaking shifted. The model a market adopts often reflects the capacity of its regulator as much as any theory of consumer choice.

Takeaway

Metal tiers standardize what a plan is worth on average, while benefit standardization standardizes what it is like to use. These are different policy goals, and confusing them leads to mismatched expectations.

The case for standardization rests on a well-documented finding: people struggle to choose insurance. Studies of Medicare Part D found that many enrollees picked plans costing more than available alternatives, often giving premiums too much weight relative to expected out-of-pocket costs. A study of employees at a large US firm went further. It found that a majority chose plans that were financially dominated, meaning worse regardless of how much care they used.

Standardization addresses the source of these errors. When cost-sharing is identical across plans, comparison narrows to a few dimensions: premium, network, and insurer quality. Research on Massachusetts' early exchange, which standardized benefit designs, found that the change meaningfully shifted which plans people chose. It also showed that how options were structured and presented mattered as much as which options existed. Choice architecture is not a neutral backdrop. It shapes outcomes directly.

The benefits are not universal, though. Fewer designs can mean a poorer fit for people with unusual needs. Someone taking an expensive specialty drug might prefer a design with different drug cost-sharing than the standardized template offers. Standardization tends to help the typical consumer most and the outlier least. And uniform cost-sharing does not remove all complexity. Networks and formularies remain hard to compare, and for some people they matter more than the deductible.

Implementation details decide much of the impact. A standardized plan buried among dozens of non-standard options delivers little clarity. This is why hybrid models rely on display tools such as labels, filters, and default sorting, and why some regulators cap the number of non-standard plans. The policy is only as effective as the shopping experience around it. Standardization changes the menu, but the website, the broker, and the decision support determine whether consumers actually benefit.

Takeaway

More options only help if people can tell them apart. Beyond a certain point, variety becomes noise, and consumers pay for it through choices that cost them money.

The economic argument for standardization is simple. When products are identical, price differences become visible. Product variation can soften price competition by making comparisons difficult, a tactic economists sometimes call obfuscation. If every gold plan carries the same cost-sharing, an insurer charging more must justify the premium through its network or service, not through a design few people can decode.

The counterargument centers on innovation. Insurers have used benefit design to experiment, for example with value-based insurance design, which lowers cost-sharing for high-value services like chronic disease medications. Fully prescribed designs freeze this experimentation unless the regulator steps in. Standardization does not end benefit innovation. It transfers that role to the exchange, which must then update designs as evidence evolves. Covered California has revised its templates over time, including expanding services covered before the deductible.

Fixing one dimension also causes competition to migrate, a kind of balloon effect. With cost-sharing locked, insurers compete on networks and formularies. Narrower networks can lower premiums, which may be a real gain, but network breadth is harder for consumers to evaluate than a deductible. Benefit design has historically been a tool for risk selection, deterring costly enrollees. Standardization removes that tool, but formulary placement and network composition still allow quieter forms of the same strategy.

Market participation is a further concern. Critics argue that rigid rules may deter insurers, especially in thin rural markets. The evidence here is mixed. Participation appears driven more by profitability, risk adjustment, and subsidy levels than by design rules alone. Context still matters. In markets with many insurers, clearer comparison can sharpen price competition. In markets with one or two carriers, choice is already limited, and the gains from easier comparison shrink accordingly.

Takeaway

Standardization does not eliminate competition; it decides where competition happens. The real policy question is whether the new arena is one consumers can actually see.

Standard plan designs are best understood as a deliberate choice about where complexity should sit. They move it away from consumers at the point of purchase and toward regulators, who must maintain designs, police networks, and keep templates current.

The evidence suggests that people make better choices among simpler menus. It also suggests that differentiation does not vanish. It moves toward networks and formularies, which call for their own oversight. A standardization policy without network transparency solves half the problem.

For health systems, the broader lesson concerns regulatory capacity. Standardization works when an exchange can act as an active steward of the market. Without that capacity, the same rules can produce uniformity without the clarity that justified them.